Deferasirox and vitamin D improves overall survival in elderly patients with acute myeloid leukemia after demethylating agents failure. - Wikidata - wikimedia - TriplyDB

Deferasirox and vitamin D improves overall survival in elderly patients with acute myeloid leukemia after demethylating agents failure.

Deferasirox and vitamin D improves overall survival in elderly patients with acute myeloid leukemia after demethylating agents failure.

http://www.wikidata.org/entity/Q34804866

about

The Potential of Vitamin D-Regulated Intracellular Signaling Pathways as Targets for Myeloid Leukemia Therapy Low oxygen tension reverses antineoplastic effect of iron chelator deferasirox in human glioblastoma cells.Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes.An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms.Vitamin D Control of Hematopoietic Cell Differentiation and Leukemia.Iron chelation: an adjuvant therapy to target metabolism, growth and survival of murine PTEN-deficient T lymphoma and human T lymphoblastic leukemia/lymphoma.Reactive oxygen species levels control NF-κB activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes.

P2860

Q26799596-937B9A00-DB94-4299-8499-B60DC8671AB0 Q35911202-F0BDAE0E-5DCD-49C4-9E99-1BBD4E1B3B1C Q38196963-4BAE6218-6EA8-4E08-8FB7-7BF509B83E1A Q38368123-297EA828-D217-4200-BBD7-70053F32891D Q39037456-7CE88594-69F8-486B-82D3-8C083B3FD252 Q46478520-5C7C08D1-FCB9-4921-9F0E-BB640658A925 Q47159669-D0DC2625-30D4-44CB-959D-B55722F6AE50

P2860

Deferasirox and vitamin D improves overall survival in elderly patients with acute myeloid leukemia after demethylating agents failure.

http://www.wikidata.org/entity/Q34804866

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Deferasirox and vitamin D impr ...... demethylating agents failure.

@ast

Deferasirox and vitamin D impr ...... demethylating agents failure.

@en

Deferasirox and vitamin D impr ...... demethylating agents failure.

@nl

type

label

Deferasirox and vitamin D impr ...... demethylating agents failure.

@ast

Deferasirox and vitamin D impr ...... demethylating agents failure.

@en

Deferasirox and vitamin D impr ...... demethylating agents failure.

@nl

prefLabel

Deferasirox and vitamin D impr ...... demethylating agents failure.

@ast

Deferasirox and vitamin D impr ...... demethylating agents failure.

@en

Deferasirox and vitamin D impr ...... demethylating agents failure.

@nl

P1433

Q34804866-72D02DE6-A19A-4137-B8B5-BC1C8686E6AB

P1476

Q34804866-CCF0757E-E2D2-4D81-B6EA-01A750A0AC91

P2093

Q34804866-2486F9F8-FBC6-45B8-B5AE-B5BB7FE8505D

Q34804866-5216657E-4647-4A64-8F1C-17F7BCAFE808

Q34804866-54360760-3E06-4D8A-AAD8-A53BEB401DFD

Q34804866-9B49E6C1-FC53-426F-BD86-DC909A5AC712

Q34804866-BB473A50-2D54-435E-974F-1FB169F198C5

Q34804866-D9F2601A-5FC1-4524-BDDB-37D486CBFCC4

Q34804866-DEDC1D5F-7E3B-4C55-A28C-7196E60A1FB5

Q34804866-E29FACAE-3609-4AC8-A99E-258A36177682

Q34804866-E3D72859-8135-4059-8815-4E74FFD2293F

Q34804866-E971091B-36D9-4F3F-8B81-7DF8210FC23E

P2860

Q34804866-06C930AF-8846-4496-9358-C286F75DB2F2

Q34804866-14BB36C5-E891-49E5-8EF9-F8626D3B87CE

Q34804866-16031012-CE90-4995-95EC-751D8D86E311

Q34804866-18963EF1-4AC2-48B3-91CC-D684C16F96AB

Q34804866-3C868459-AA3A-4B9C-AFDC-90A4B1CDC29C

Q34804866-3FC9015A-6AEE-464C-BAE9-61E7ADBFEB3F

Q34804866-55CCA4FA-7F66-4022-9B4B-8379B3454620

Q34804866-6AF513A8-785D-4618-9324-84C2313981AF

Q34804866-7BE9D6DC-504C-45D0-8895-09847E55B9A9

Q34804866-89C40E70-B9FC-460D-A10E-69942FB2B8CF

P304

Q34804866-2972F9BD-5A0D-4B2D-800E-D9AAA529C790

P31

Q34804866-A5EC3074-314C-43D6-A259-9267226AD143

P356

Q34804866-E9F7B82E-97FE-4C3E-8A66-BC8CFE41B2B0

P407

Q34804866-79C74A56-D81E-4B4E-94EF-BA457B37B4C1

P433

Q34804866-EC7430EF-62FA-4B10-95EE-7D8BADDC8FE7

P478

Q34804866-EA9F6DCE-7B38-42F5-AC61-4AD767C58EE6

P50

Q34804866-30998332-AEB5-469C-9E87-F6428AC07122

Q34804866-35BE87FE-8727-4ADB-A12D-B5BE48806C6E

Q34804866-4AB75DC3-EEFB-4E38-92E9-1A799C56027E

Q34804866-AAE4BF3C-98B0-4E11-BCB7-B33A14D0709E

P577

Q34804866-D8A2D3AD-65FD-4C29-9876-4F176DFEF960

P5875

Q34804866-ACB870AD-F88B-4FFC-93F7-BCB0A835F164

P698

Q34804866-4EFDFF3E-B5A3-4412-A4DD-31A3B051B1BD

P921

Q34804866-35FA4D03-5AE7-495B-BBE5-F9A12BEBF52A

Q34804866-3CD88F6D-7034-484E-B8E4-4659DFBF3456

P932

Q34804866-CCA8E3B1-86AD-474C-A18A-AE418BE9012D

P356

JOURNAL.PONE.0065998

P1433

P1476

Deferasirox and vitamin D impr ...... demethylating agents failure.

@en

P2093

Céline Callens

http://www.w3.org/2001/XMLSchema#string

Etienne Paubelle

http://www.w3.org/2001/XMLSchema#string

Felipe Suarez

http://www.w3.org/2001/XMLSchema#string

Florence Zylbersztejn

http://www.w3.org/2001/XMLSchema#string

Françoise Isnard

http://www.w3.org/2001/XMLSchema#string

Gandhi Damaj

http://www.w3.org/2001/XMLSchema#string

Marie-Thérèse Rubio

http://www.w3.org/2001/XMLSchema#string

Michaël Dussiot

http://www.w3.org/2001/XMLSchema#string

Norbert-Claude Gorin

http://www.w3.org/2001/XMLSchema#string

Sawsaneh Alkhaeir

http://www.w3.org/2001/XMLSchema#string

P2860

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties

Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.

Acute myeloid leukemia.

Vitamin D3-driven signals for myeloid cell differentiation--implications for differentiation therapy

Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia.

Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging

Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B.

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia

P304

e65998

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0065998

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Olivier Hermine

Renato Monteiro

Jean-Pierre Marolleau

P577

2013-06-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

248385470

http://www.w3.org/2001/XMLSchema#string

P698

23840388

http://www.w3.org/2001/XMLSchema#string

P921

P932

3688707

http://www.w3.org/2001/XMLSchema#string